Welcome to Lycera Corp

Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders and cancer. Lycera’s technology focuses on proprietary small molecules that modulate a target, which is central to bioenergetic processes within cells. Steroid-like efficacy has been demonstrated in a range of pre-clinical models. Drugs that emerge from the Lycera pipeline will represent first-in-class agents that are anticipated to have significant advantages over competitive products, including better efficacy, fewer side effects, ease of administration.

News & Updates

Dr. Douglas Green, renown immunologist joins Lycera SAB

QUICKLINKS